Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
Palisade Bio (Nasdaq: PALI) announced its participation in the 8th Annual Antifibrotic Drug Development Summit in Boston, MA, from November 19-21, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palisade Bio (Nasdaq: PALI) announced its participation in the 8th Annual Antifibrotic Drug Development Summit in Boston, MA, from November 19-21, 2024. Chief Medical Officer Mitch Jones, MD, PhD, will present on fibrostenotic Crohn's Disease and local PDE4 inhibitor prodrug development on November 21 at 2:30 PM ET.
The presentation, titled 'Detailing Characteristics of Fibrostenotic Crohn's Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy,' will be part of the session examining latest research in antifibrotic development. The AFDD Summit is a key forum bringing together experts in antifibrotic drug development.
Details
News Market Reaction – PALI
The recorded move for PALI in the trading session of this news was +19.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition
Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has been invited to present at the 8th Annual Antifibrotic Drug Development (AFDD) Summit, being held November 19-21, 2024, in Boston, MA.
Details of the presentation details are as follows:
Title: Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy
Presenter: Mitch Jones, MD, PhD, Chief Medical Officer of Palisade Bio
Session: Examining the Latest Research & Development in Antifibrotic Research & Development
Date and Time: November 21, 2024 from 2:30-3:00 PM ET
The AFDD Summit is a leading forum for experts in the field of antifibrotic drug development, bringing together clinicians, researchers, and pharmaceutical leaders to discuss the latest advancements in treating fibrosis-related diseases. For more information about the AFDD Summit, please visit the conference website.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.